Physician profile
Michael W Reder
NPI 1700837259
$428.11
in general payments reported to CMS, 2019-2025
13 companies · $21.44 in 2025
The $21.44 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.58 · 2020: $19.49 · 2021: $107 · 2022: $154 · 2023: $82.94 · 2024: $26.15 · 2025: $21.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $130.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $108.07 | 2019-2023 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $87.51 | 2022-2023 | Takhzyro, Hyqvia |
| Astrazeneca Pharmaceuticals LP | $35.42 | 2022-2025 | Fasenra |
| Abbvie INC. | $28.12 | 2022 | |
| Csl Behring | $26.15 | 2024 | Haegarda |
| Uswm, LLC | $24.00 | 2021 | |
| Kaleo, INC. | $21.34 | 2022 | |
| Leo Pharma INC. | $20.02 | 2022 | |
| Genzyme Corporation | $18.88 | 2022 | |
| Genentech USA, INC. | $16.73 | 2021 | |
| Biocryst US Sales Co., LLC | $15.32 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.58 | 2023 | Dupixent |
| Horizon Therapeutics Plc | $12.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Reder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.